Handok, Genexine secure majority stake in US biotech company
Jan 9, 2019
Korean pharma companies Handok and Genexine became joint majority stakeholders in US biopharmaceutical group Rezolute through a 50-50 joint investment of 28 billion won ($24.9 million), Handok announced Tuesday.Handok and its subsidiary Genexine now together hold 54 percent of Rezolute. The deal will allow the Korean pharma firms to acquire information about the work Rezolute has undertaken in biopharmaceutical development, and may also serve as a bridge to the US market. (Yonhap)Rezolute, estab